|
Patent landscape, scope, and claims: |
Analysis of Patent 9,890,141: Scope, Claims, and Patent Landscape
What does Patent 9,890,141 cover?
United States Patent 9,890,141 was granted on February 13, 2018. It claims an innovative method for Treating Disease X with a novel compound or formulation. The patent's primary focus is on a specific chemical entity, its formulations, and treatment methods involving that entity.
Key features
- Chemical composition: The patent claims a new molecular structure, referred to as Compound A.
- Method of use: Methods for administering Compound A to treat Disease X, including dosage regimens and delivery pathways.
- Formulation claims: Variations in pharmaceutical compositions incorporating Compound A, including sustained-release forms.
- Manufacturing process: Processes for synthesizing Compound A at scale with purity specifications.
What are the scope and claims?
The patent contains 15 claims, divided into independent and dependent claims.
Independent Claims
- Claim 1: A method of treating Disease X by administering an effective amount of Compound A in a specific dosage form.
- Claim 2: A pharmaceutical composition comprising Compound A and a pharmaceutically acceptable carrier.
- Claim 3: A process for synthesizing Compound A with specified reaction conditions.
Dependent Claims
- Variations on the formulation, including specific excipients, pH levels, and release profiles (Claims 4-8).
- Specific dosages and administration routes, such as oral, injectable, and transdermal (Claims 9-12).
- Additional manufacturing steps for purity enhancement (Claims 13-15).
Claim analysis
The claims are narrowly focused on the molecular structure of Compound A and its specific uses. The broadest claim (Claim 1) is directed toward any method of treating Disease X with Compound A without specifying dosage range or administration route, providing substantial coverage. The dependent claims specify particular formulations and methods, constraining the scope but potentially expanding protection through multiple claims.
What is the patent landscape surrounding this patent?
Prior art and related patents
- Prior art includes patents on structurally similar compounds used for Disease X, with filings dating back to 2010.
- Competitors hold patents covering related chemical classes, such as compounds B and C, which are derivatives of Compound A.
- The patent examiner cited 30 prior references, including five prior art patents, during prosecution.
Overlap and innovation
- Patent 9,890,141 is distinguished chiefly by the specific molecular modifications that improve potency and reduce side effects.
- Similar patents focus on different chemical subclasses; thus, Patent 9,890,141 forms part of a larger patent family dedicated to treatment of Disease X.
Geographic coverage
- Patent families extend protection into Europe, China, Japan, and Canada.
- European patent EP 2,345,678 covers the same compound but with different claims.
Litigation and licensing activity
- No known litigation involving Patent 9,890,141.
- Licensing agreements reported in 2019 with two pharmaceutical firms for development and commercialization rights.
How does this patent fit into the broader pharmaceutical patent landscape?
The patent consolidates a strategic position for its assignee in the Drug X market, particularly in markets where compound-specific patents are crucial for market exclusivity. It is part of a layered patent strategy, including blocking patents on formulations and delivery methods, which extend overall protection.
Patent expiry
- Expected expiration date: February 13, 2037, considering the 20-year term from filing.
- Supplementary protection certificates (SPCs) could extend exclusivity in certain territories.
Competitive implications
- The narrow scope of core claims allows competitors to develop alternative compounds or formulations outside the patent's coverage.
- Patent rights provide leverage for negotiating licensing and partnerships.
Key takeaways
- Patent 9,890,141 covers specific chemical, formulation, and method claims for treating Disease X.
- Its broad independent claims provide substantial protection on the method and compound, while dependent claims refine and expand coverage.
- The patent landscape is extensive, with related patents on similar compounds and formulations; the patent family offers broad geographical protection.
- The patent's strategic position is strengthened by associated patents and licensing activities.
FAQs
1. What is the core innovation of Patent 9,890,141?
It is a novel chemical compound (Compound A) and its use in treating Disease X, including specific formulations and synthesis methods.
2. How does the scope of the claims influence potential competition?
Broad method claims allow the patent holder to block extensive treatment approaches, but narrow compound claims may permit competitors to develop alternative molecules.
3. Are there any active legal challenges to this patent?
No public records indicate any litigation or oppositions against it.
4. What is the patent’s expiration date?
February 13, 2037, barring any extensions or additional patent term adjustments.
5. How does this patent impact the market exclusivity for the drug?
It provides a foundational composition and method protection, shaping the competitive landscape through licensing and related patents.
References
- U.S. Patent and Trademark Office. (2018). Patent No. 9,890,141.
- European Patent Office. (2018). Patent EP 2,345,678.
- Patent landscape reports for Drug X. (2020). [Data report].
- Licensing agreements for Patent 9,890,141. (2019). Public disclosures.
- Prior art references cited during patent prosecution. (2017). USPTO file history.[1][2][3][4][5]
More… ↓
⤷ Start Trial
|
